Labor analgesia using continuous epidural infusions of low-dose bupivacaine and fentanyl may be maintained for many hours. We examined the potential for drug accumulation in both mother and neonate after these long-term infusions. Pregnant women receiving a lo-mL/h continuous infusion of labor analgesia with 0.125% bupivacaine and 2 pg/mL of fentanyl were evaluated. Maternal venous and umbilical venous drug concentrations were measured at delivery. Umbilical artery blood gases were obtained. Scanlon
C ontinuous epidural infusions containing a combination of low concentrations of local anesthetic and narcotic have become increasingly popular for labor analgesia. The use of these infusions has several advantages. Fentanyl and bupivacaine in combination provide analgesia equivalent to that produced by more concentrated local anesthetic solutions without fentanyl (l), so that a lower total dose of local anesthetic will be required. Dilute local anesthetic solutions mixed with fentanyl will also produce less motor block in the parturient than the more concentrated local anesthetic solutions.
In some patients, these epidural infusions may be maintained for many hours. Information on drug accumulation in mother and neonate during these longterm infusions is limited. One study reported mean maternal and fetal bupivacaine levels at delivery in a group of parturients who received epidural infusions of plain 0.125% bupivacaine for an average of 7 h (2). There are no data regarding fentanyl concentrations after long-term epidural analgesia.
The present study was undertaken to examine the potential for drug accumulation of bupivacaine and fentanyl when a low-dose infusion is continued for many hours. Maternal and umbilical drug levels at neurobehavioral testing was performed on all infants. Length of infusion times varied from 1 to 15 h. Maternal and neonatal drug concentrations remained relatively constant throughout the infusion period. All umbilical blood gas values and neurobehavioral scores were within normal limits. In conclusion, even when maintained for many hours, continuous infusion labor analgesia does not appear to result in significant fetal drug accumulation.
No adverse neonatal effects were seen. (Anesth Analg 1995; 81:829-32) delivery were measured and correlated with length of infusion time.
Methods
Approval was obtained from the hospital's Committee for the Protection of Human Subjects and written, informed consent was obtained from all participants. Twenty-eight healthy ASA class I parturients at term in Stage 1 of labor were enrolled. After routine intravenous hydration with 500-1000 mL of lactated Ringer's solution, all participants had an epidural catheter placed through a 17-gauge Weiss needle. After an initial test dose of 3 mL of 0.25% bupivacaine, an additional 7 mL was given incrementally for a total initial dose of 10 mL of 0.25% bupivacaine. No fentanyl was included in the initial bolus. This would ensure that the catheter was indeed properly placed and functional. All participants then received a continuous infusion of 0.125% bupivacaine with 2 pg/mL of fentanyl at a constant rate of 10 mL/h, which is the labor infusion in standard use at our institution. The lowdose infusion used was therefore 12.5 mg/h of bupivacaine and 20 pg/h of fentanyl. the subsequent determination of bupivacaine and fentanyl concentrations. Blood samples were centrifuged and the plasma was separated into two separate aliquots and stored in polypropylene tubes at -20°C until analysis. Bupivacaine concentrations were determined using a gas chromatographic technique (3). In our laboratory the coefficient of variation of this assay is typically 5%-10% over the concentration range studied (0.05-1.00 kg/mL). Fentanyl plasma concentrations were determined using a commercially available radioimmunoassay kit (Research Diagnostics, Inc., Flanders, NJ). The minimum detectable limit of this assay was 0.1 ng/mL with a coefficient of variation ranging from 18% at 0.1 ng/mL to 10% at 2 ng/mL. Fentanyl concentrations were determined from a standard curve derived daily from a series of seven known standard concentrations. A sample of umbilical artery blood was drawn for subsequent blood gas analysis and Apgar scores at 1 and 5 min were recorded. Scanlon Neonatal Neurobehavioral testing (4) was performed on all neonates by a pediatrician during the first hour of life. The length of infusion time was correlated with drug concentrations using linear regression analysis. A P value co.05 was considered to be statistically significant.
Results
Twenty-one parturients were included in the study. The length of infusion times in these patients ranged from 70 min to approximately 15 h. The total dose of epidural drug received varied from approximately 27 mg of bupivacaine and 22 pg of fentanyl in the patient with the shortest infusion time to 200 mg of bupivaCaine and 300 pg of fentanyl in the patient with the longest infusion time. All of the patients in the study had satisfactory analgesia for labor and did not require additional anesthesia for delivery. A total of 28 patients were initially enrolled, but seven who required forceps or cesarean delivery were excluded. Mean bupivacaine and fentanyl concentrations and UV/MV ratios for the study are described in Table 1 . With increasing infusion times, there were no statistically significant increases in UV fentanyl or bupivaCaine concentrations (Figures 1 and 2) . Maternal bupivacaine and fentanyl concentrations also did not show a statistically significant increase over the infusion period. Similarly, the UV/MV ratios for both drugs did not change significantly over the infusion times studied (Figure 3) .
Apgar scores, neurobehavioral testing, and umbilical artery blood gas values were within normal limits in all cases. All Apgar scores at 1 and 5 min were 8 or greater. Mean umbilical artery and venous blood gas values were as follows: pH 7.26 t 0.03 and 7.33 ? 0.03; PO, 17.6 ? 8.4 mm Hg and 25.0 +-5.3 mm Hg; Pco, 53.0 ? 9.9 mm Hg and 44.3 i-3.2 mm Hg, respectively.
Discussion
These results suggest that the use of continuous infusion epidural analgesia for labor with low-dose bupivacaine and fentanyl over periods of up to 15 h does not result in significant drug accumulation in either mother or neonate. Although there are no comparable data for fentanyl, our bupivacaine data are consistent with previous work. Table 1 compares our results with those of Abboud et al. (2) who observed patients receiving 0.125% bupivacaine at a rate of 14 mL/h. The MV and UV concentrations of bupivacaine obtained in that study, as well as the UV/MV ratios, were very similar to those reported here. The low UV/MV ratio reported in these in viva studies for bupivacaine probably reflects its lipophilicity and relatively high degree of protein binding. Recent in vitro studies examining isolated human placental cotyledons support these theories, demonstrating a mean fetomaternal concentration gradient of 0.58 (5). Although bupivacaine crossed from the MV to the fetal reservoir rapidly in their study, the fetomaternal concentration gradient was low, suggesting placental deposition of this highly lipid soluble agent.
Preston et al. (6) observed umbilical cord fentanyl concentrations after one dose of 1 pg/kg of fentanyl administered epidurally for cesarean delivery (5). Plasma concentrations exceeding 0.1 ng/mL were found in none of the 13 umbilical artery samples and in only 1 of the 13 umbilical venous samples where the level was 0.24 ng/mL. Carrie and O'Sullivan (7) administered a bolus dose of 150-200 pg of epidural fentanyl and reported umbilical artery fentanyl concentrations ranging from 0.1 to 0.25 ng/mL with a median value of 0.18 ng/mL, which is similar to the UV concentration of the present study (0.16 ng/mL). UV values and dose to delivery intervals were not reported in this study.
The UV/MV ratio for fentanyl in our study is quite high, approaching unity. This would suggest that placental transfer of fentanyl is rapid and UV concentrations equilibrate with those in maternal venous blood. Fentanyl is a highly lipid soluble drug which would be expected to cross the placenta easily and rapidly equilibrate between the maternal and fetal circulations. Concentrations of fentanyl in the UV were low during the infusions.
Recent animal data support these theories. Animal studies examining maternal and fetal fentanyl concentrations l-60 min after bolus administration indicate that there is a rapid decline in maternal concentrations reflecting rapid redistribution and uptake by maternal tissues with a parallel concentration profile being exhibited by the fetus; fetal decline parallels maternal decline (8). The UV/MV ratio in our study approached unity and did not change significantly with longer infusion times. Recent studies on in vitro human placental uptake and transfer of fentanyl report equal maternal-to-fetal and fetal-to-maternal clearances of fentanyl (9). These authors used an in vitro human placental model to study transfer of fentanyl and found that a plateau was reached within 40-80 min of continuous infusion. They suggested passive transport for fentanyl across the placenta. A high placental tissue fentanyl content was found, implying that the placenta serves as a depot for fentanyl. To date, there is no known interaction between bupivacaine and fentanyl promoting or interfering with placental transfer of the other drug. Both MV and UV fentanyl concentrations in our study were low, and higher UV fentanyl levels did not correlate with longer infusion times or lower umbilical pH values.
We did not attempt to measure fetal tissue accumulation of bupivacaine, and one might postulate that the low UV/MV ratio may in part be due to uptake by fetal tissues. The significance of fetal tissue uptake of bupivacaine is unclear. Tissue uptake by the nonvital organs of the fetus may actually help prevent higher bupivacaine levels in fetal brain and myocardium. There is some evidence that the infant is able to metabolize and excrete bupivacaine similarly to the adult (10). Neonatal urine has small but measurable levels of bupivacaine metabolites for 36 h after delivery (11). The absence of demonstrable neurobehavioral effects would speak against significant central nervous system accumulation in the neonates studied.
None of the neonates evidence of respiratory in our study showed any depression.
In a previous study, one neonate with an umbilical artery fentanyl concentration of 0.25 ng/mL required ventilation and naloxone administration; however, other neonates with similar fentanyl concentrations did not have respiratory problems (7).
In summary, the current practice of providing labor analgesia using continuous infusions of low-dose bupivacaine and fentanyl results in equilibration of these drugs across the placenta at relatively constant W/MV ratios. Concentrations of both drugs remained relatively low. None of the neonates, even after long infusion periods, showed any significant accumulation of drug or adverse effects as demonstrated by umbilical blood gases and neurobehavioral scores.
